Insmed Inc., of Bridgewater, N.J., said revenue from Arikayce (amikacin liposome inhalation suspension) totaled $36.9 million for the first quarter. Global growth and label-expansion efforts are advancing, the firm said. The company is fighting the pandemic by supporting an investigator-initiated study of brensocatib, formerly known as INS-1007, in patients with severe COVID-19 infection. Insmed reported a GAAP net loss of $66.4 million, or 74 cents per share, for the first quarter, compared to a GAAP net loss of $74.2 million, or 96 cents per share, for the same period in 2019. As of March 31, the company had $428.9 million on its balance sheet. Shares of Insmed (NASDAQ:INSM) closed April 30 at $23, up $1.95.